Loading...
•
Jun 30, 2025
Axsome Q2 2025 Earnings Report
Axsome reported strong revenue growth in Q2 2025, led by AUVELITY and the launch of SYMBRAVO, despite posting a net loss.
Key Takeaways
Axsome delivered solid revenue growth in Q2 2025, driven by continued momentum in AUVELITY and SUNOSI, and the launch of SYMBRAVO, while managing a reduced net loss year-over-year.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Axsome expects current cash to fund operations into cash flow positivity, with key regulatory submissions and clinical trial initiations planned for H2 2025.
Positive Outlook
- Cash expected to fund operations into cash flow positivity
- sNDA submission for AXS-05 in Alzheimer’s agitation on track for Q3 2025
- NDA submission for AXS-12 in narcolepsy expected in Q4 2025
- Launch of SYMBRAVO expected to gain traction with new GPO contract
- AUVELITY and SUNOSI continue to show strong prescription growth
Challenges Ahead
- Company still operating at a net loss
- High SG&A expenses due to commercialization
- Stock-based compensation impacted net results
- No specific free cash flow guidance provided
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...